Codiak BioSciences Files For Chapter 11 Bankruptcy - Yahoo Finance
2023-03-27 • Google News
Codiak BioSciences Inc (CDAK)
US$ 1.67-6.7%
Price Chart
Key Statistics
Market Cap
$ 2.83M
P/E Ratio
0.00
Revenue (TTM)
$ 34.07M
Volume
222.68K
52W High
$ 0.00
52W Low
$ 0.00
Dividend Yield
0.00%
Beta
3.94
Technicals
50-Day MA
0.4073
200-Day MA
1.0006
52 Week High
N/A
52 Week Low
N/A
About CDAK
Codiak BioSciences, Inc., a clinical-stage biopharmaceutical company, focuses on developing exosome-based therapeutics for the treatment of oncology, neuro-oncology, neurology, neuromuscular diseases,.
Employees
102
Headquarters
Cambridge, MA
CEO
Dr. Douglas Edward Williams Ph.D.
Latest News
Codiak Announces Pricing of $57.8 Million Public Offering of Common Stock - GlobeNewswire
2021-02-11 • Google News
Cash-strapped biotech firm Codiak files for bankruptcy protection - Reuters
2023-03-27 • Google News
Top Gainers
Symbol/Name
LTP
% Chg
Top Losers
Symbol/Name
LTP
% Chg